Compass Pathways Plc (CMPS)
13.23
-0.01
(-0.08%)
USD |
NASDAQ |
Sep 02, 16:00
13.20
-0.03
(-0.23%)
After-Hours: 20:00
Compass Pathways Research and Development Expense (Annual) : 118.71M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 118.71M |
| December 31, 2024 | 119.09M |
| December 31, 2023 | 87.86M |
| December 31, 2022 | 65.01M |
| Date | Value |
|---|---|
| December 31, 2021 | 44.02M |
| December 31, 2020 | 23.37M |
| December 31, 2019 | 12.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Silence Therapeutics Plc | 60.29M |
| Biodexa Pharmaceuticals Plc | 5.026M |
| NuCana Plc | 16.79M |
| Mereo BioPharma Group Plc | 17.81M |
| HemoGenyx Pharmaceuticals Plc | -- |